An NKCE, known as NKG2CxIL-15xCD33, comprising an anti-NKG2C scFv and an anti-CD33 scFv, linked by a wild-type IL-15 in the middle (62), has demonstrated satisfactory NK cell activation, expansion, and cytotoxicity against CD33+ myeloid leukaemia cells both in vitro and in vivo in an NSG mouse model (62). This evidence concerns the gene CD33 and myeloid leukemia.